Pre-TED Disease Classification Form (Form 2402): Transformation to Myelofibrosis

An important update has been made to the Forms Instructions Manual concerning the transformation of essential thrombocythemia (ET) or polycythemia vera (PV) to myelofibrosis prior to transplant. The following notes have been added to the Pre-TED Disease Classification instructions:
Myelodysplastic (MDS / Myeloproliferative (MPN) Disease
A note has been added underneath header for the MDS / MPN disease classification questions (Q122-215).  It states:
Recipients transplanted for post-essential thrombocythemia myelofibrosis (post-ET MF) or post-polycythemia vera myelofibrosis (post-PV MF) will be reported as ET or PV at diagnosis (Q122). Question 167: 'Did the recipient progress or transform to a different MDS/MPN subtype between diagnosis and the start of the preparative regimen?' must be answered "yes".
Question 167: Did the recipient progress or transform to a different MDS/MPN subtype between diagnosis and the start of the preparative regimen?
A note has been added underneath question 167.  It states:
Myelofibrosis that develops in patients with essential thrombocythemia (ET) or polycythemia vera (PV) is considered secondary myelofibrosis.  However, effective immediately, cases of post-essential thrombocythemia myelofibrosis (post-ET MF) or post-polycythemia vera myelofibrosis (post-PV MF) will now be reported as "Primary Myelofibrosis (PMF)" at the time of HCT.  In order to capture accurate data, the secondary MF cases need to be lumped in with the PMF cases, since treatment for post-ET MF and post-PV MF is the same as PMF.
Questions, feedback, or requests may be submitted directly on the manual website using the Feedback Feature at the bottom of each page. For more information on how to submit feedback, click here .